Browse by Series:

Addressing the Unmet Needs for the Treatment of CLL

Panelists: Susan M. O'Brien
Published: Wednesday, Jun 27, 2018



Transcript: 

Susan M. O’Brien, MD: One of the historically and most important unmet needs in chronic lymphocytic leukemia was the fact that we needed therapy for patients with deletion 17p. That is because all our therapies, up until very recently, were chemotherapy based, and we know that those patients have very poor response rates. If they do get a response, they have very short remission duration. That unmet medical need, to some extent, has now been met, I would say, with the small molecules ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta). What we’re looking at now is not necessarily small patient subsets but how we cure the larger population with CLL. There may be a cure fraction in the mutated IGHV patients with FCR (Fludarabine/cyclophosphamide/rituximab), but that accounts for a very small percentage of the patients.

Transcript Edited for Clarity
Slider Left
Slider Right


Transcript: 

Susan M. O’Brien, MD: One of the historically and most important unmet needs in chronic lymphocytic leukemia was the fact that we needed therapy for patients with deletion 17p. That is because all our therapies, up until very recently, were chemotherapy based, and we know that those patients have very poor response rates. If they do get a response, they have very short remission duration. That unmet medical need, to some extent, has now been met, I would say, with the small molecules ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta). What we’re looking at now is not necessarily small patient subsets but how we cure the larger population with CLL. There may be a cure fraction in the mutated IGHV patients with FCR (Fludarabine/cyclophosphamide/rituximab), but that accounts for a very small percentage of the patients.

Transcript Edited for Clarity
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x